News2020-02-23T23:18:18-05:00
Page-TitleNEWS

Virpax to Develop Its Molecular Envelope Technology (MET) Intranasal Enkephalin Formulation for the Management of PTSD

Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with Nanomerics Ltd. Under the agreement, Virpax has exclusive global rights to use Nanomerics’ nanotechnology for the delivery of a metabolically labile intranasal [...]

January 14th, 2020|Press Release|

Michèle C. Linde Promoted to EVP, Global Corporate Governance, Chief Legal Officer & Corporate Secretary for Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that Michèle C. Linde has been promoted to EVP, Global Corporate Governance, Chief Legal Officer & Corporate Secretary effective immediately. “This promotion reflects our company's commitment to excellence,” said Anthony P. Mack, [...]

October 20th, 2019|Press Release|

Virpax Pharmaceuticals Announces the Appointment of Three Independent Directors

Virpax Pharmaceuticals Inc. (“Virpax”) a company specializing in developing pharmaceutical products for pain management, is pleased to announce the appointment of three independent directors: Eric Floyd, PhD, Jerrold Sendrow, CFP and Thani Jambulingam, PhD, at their Annual General Meeting of the Shareholders held on Monday, September 9, 2019 [...]

September 10th, 2019|Press Release|

Virpax Pharmaceuticals Licenses ‘Patch-in-a-Can’ MedSpray® Technology From MedPharm Ltd

Transdermal Delivery Technology Integrated Into DSF100 NSAID Spray Film 1.3% Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with MedPharm Ltd, a leading contract provider of topical and transdermal product design and [...]

May 29th, 2018|Press Release|